** Shares of biotech firm Humacyte HUMA.O down 23.5% premarket to $2.20, over 16-mth low, after overnight follow-on priced
** Durham, North Carolina-based co late Tues sold 25 mln shares at $2 for $50 mln gross raise
** Offering priced at 30.6% discount to last sale
** Co intends to use net offering proceeds to fund commercialization of its implant Symvess for patients with extreme blood vessel injury
** U.S. FDA granted approval of Symvess in Dec
** HUMA has ~122.7 mln shares outstanding for ~$353 mln market cap, and ~89.7 mln shares of public float, per LSEG data
** TD Cowen, Barclays and BTIG jt bookrunners for the offering
** Through Tues, HUMA shares down 43% YTD after ~78% gain in 2024
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。